Global Companion Diagnostics Market - Drivers' Restraints' Opportunities' Trends' and Forecasts: 2018-2024
Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease' predict drug toxicities' off-target effects of treatment' and other adverse effects related to the drug. It is also used during clinical trials to guide treatment' which can improve therapy responses and treatment outcomes. Currently' there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute' in the US' around 1.6 million new cases of cancer were diagnosed and 595'690 people have died due to cancer in 2016. According to the Canadian Cancer Society' 202'400 new cases of cancer and nearly 78'000 deaths were recorded in 2016. While in Europe' 1.3 million people were diagnosed in 2015. Further' according to the study of World Health Organization' approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle' which is expected to fuel the growth of the companion diagnostics market in coming years.
The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally' high adoption of companion diagnostics' growing demand for companion diagnostics' and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.
Market Analysis: The "Global Companion Diagnostics" market is estimated to witness a CAGR of 19.6% during the forecast period 2018-2024. The market is analyzed based on four segments - technology' applications' end-users' and regions.
Regional Analysis: The regions covered in the report are North America' Europe' Asia Pacific' and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe' Asia Pacific' and Rest of the World.
Technology Analysis: The global companion diagnostics market' by technology' is segmented into polymerase chain reaction' immunohistochemistry' in-situ hybridization' next-generation sequencing' and others. Polymerase chain reaction occupied the largest share in 2017' and next-generation sequencing is expected to grow at a high CAGR in the coming years.
Application Analysis: The global companion diagnostics market' by application' is segmented into cancer' infectious disease' and others. The cancer application is further segmented into colorectal cancer' breast cancer' lung cancer' melanoma' and others. In 2017' cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer' changing lifestyle' and growing
For instance' in February 2017' Roche announced the launch of Elecsys AMH Plus immunoassay' the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance' in June 2017' the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the Oncomine Dx Target test' which instantaneously evaluates 23 genes clinically related to NSCLC.
Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that' key stakeholders can know about the major trends' drivers' investments' vertical player's initiatives' government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover' the report provides details about the major challenges that are going to impact on the market growth. Additionally' the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Region/Country Cover in the Report
Regions-North America' Europe' Asia Pacific' and Rest of the World
Key Players Covered in the Report
F. Hoffmann-La Roche Ltd' Qiagen N.V.' Abbott Laboratories' Myriad Genetics' Agilent Technologies' Inc.' BioMerieux S.A.' Danaher Corporation (Leica Microsystems AG)' Resonance Health Limted' Thermo Fisher Scientific' Inc.' Genomic Health' Inc
